Free Trial

IN8bio (INAB) Competitors

IN8bio logo
$2.28 +0.04 (+1.56%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INAB vs. ENLV, SLGL, ATNF, ACRV, GBIO, PEPG, XCUR, EGRX, RENB, and HYPD

Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Enlivex Therapeutics (ENLV), Sol-Gel Technologies (SLGL), 180 Life Sciences (ATNF), Acrivon Therapeutics (ACRV), Generation Bio (GBIO), PepGen (PEPG), Exicure (XCUR), Eagle Pharmaceuticals (EGRX), Renovaro (RENB), and Hyperion DeFi (HYPD). These companies are all part of the "pharmaceutical products" industry.

IN8bio vs. Its Competitors

IN8bio (NASDAQ:INAB) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IN8bioN/AN/A-$30.44M-$9.11-0.25
Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.50

In the previous week, Enlivex Therapeutics had 4 more articles in the media than IN8bio. MarketBeat recorded 6 mentions for Enlivex Therapeutics and 2 mentions for IN8bio. IN8bio's average media sentiment score of 0.44 beat Enlivex Therapeutics' score of 0.23 indicating that IN8bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IN8bio
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enlivex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

IN8bio presently has a consensus price target of $180.00, indicating a potential upside of 7,812.09%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 910.10%. Given IN8bio's higher probable upside, analysts plainly believe IN8bio is more favorable than Enlivex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IN8bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

IN8bio has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Enlivex Therapeutics' return on equity of -57.67% beat IN8bio's return on equity.

Company Net Margins Return on Equity Return on Assets
IN8bioN/A -184.97% -126.75%
Enlivex Therapeutics N/A -57.67%-50.52%

Summary

Enlivex Therapeutics beats IN8bio on 9 of the 14 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INAB vs. The Competition

MetricIN8bioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.33M$3.09B$5.82B$9.75B
Dividend YieldN/A2.23%3.84%4.09%
P/E Ratio-0.2521.0131.1425.96
Price / SalesN/A396.98475.48122.90
Price / CashN/A43.0937.1558.38
Price / Book0.688.069.116.38
Net Income-$30.44M-$54.72M$3.26B$265.56M
7 Day Performance-4.01%2.30%1.94%1.81%
1 Month Performance-4.01%7.21%4.91%1.14%
1 Year Performance-85.42%12.85%31.21%20.98%

IN8bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INAB
IN8bio
3.9142 of 5 stars
$2.28
+1.6%
$180.00
+7,812.1%
-86.2%$10.33MN/A-0.2520Short Interest ↓
ENLV
Enlivex Therapeutics
3.3517 of 5 stars
$1.25
-31.3%
$10.00
+700.0%
-16.3%$43.04MN/A-1.8970Upcoming Earnings
Short Interest ↓
High Trading Volume
SLGL
Sol-Gel Technologies
1.0982 of 5 stars
$16.10
+4.3%
$40.00
+148.4%
+330.0%$43.01M$11.54M-13.0950News Coverage
Positive News
Earnings Report
Gap Down
Trading Halted
ATNF
180 Life Sciences
0.5372 of 5 stars
$7.27
-4.5%
N/A+173.8%$42.52MN/A-0.487
ACRV
Acrivon Therapeutics
2.7691 of 5 stars
$1.39
+3.0%
$17.57
+1,164.1%
-85.6%$42.47MN/A-0.6258
GBIO
Generation Bio
3.3133 of 5 stars
$6.63
+5.4%
$10.67
+60.9%
-75.8%$42.37M$19.89M-0.61150Gap Up
PEPG
PepGen
2.7442 of 5 stars
$1.30
+0.8%
$7.67
+489.7%
-87.3%$42.31MN/A-0.4430
XCUR
Exicure
1.9585 of 5 stars
$6.55
-1.5%
N/A+1,509.1%$42.01M$500K-1.6950Gap Up
EGRX
Eagle Pharmaceuticals
1.8302 of 5 stars
$3.20
flat
N/A-26.0%$41.56M$257.55M0.00100
RENB
Renovaro
1.2834 of 5 stars
$0.23
-3.3%
N/A-64.8%$41.15MN/A-0.3020
HYPD
Hyperion DeFi
0.3011 of 5 stars
$7.46
+3.6%
$2.00
-73.2%
-83.6%$41M$60K-0.1340Gap Down

Related Companies and Tools


This page (NASDAQ:INAB) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners